Countries China

Belief BioMed Completes First Dosing in Hemophilia A Trial

BBM-H803 is Belief BioMed's first gene therapy for the treatment of hemophilia A and is the company's second product which has obtained IND approval from t...

 January 04, 2024 | News

WuXi XDC Partners with IntoCell to Boost ADC Discovery and Development

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel...

 January 03, 2024 | News

MediLink Therapeutics Partners with Roche for Oncology Antibody Drug Conjugate

Under the terms of the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's...

 January 03, 2024 | News

Biocytogen, CtM Bio Make Strides in TCR-Mimic Antibody Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd ("CtM Bio") jointly announce tha...

 January 01, 2024 | News

Clover's SCB-219M Shows Positive Phase I Results for Chemotherapy-Induced Thrombocytopenia (CIT) Treatment

--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses t...

 December 29, 2023 | News

RemeGen's RC88 Granted FDA IND Approval for Platinum-Resistant Ovarian Cancer

  The open-label, randomized, dose optimization phase 2 study aims to enroll participants in multiple countries to further clarify the optimal dosage...

 December 29, 2023 | News

Innovent and Xuanzhu Collaborate on Clinical Trial for Combined Therapy in Chinese Solid Tumor Treatment

Under the agreement, Innovent will supply sintilimab for the collaborated clinical trial. Xuanzhu Biopharma will conduct a Phase 1b clinical stud...

 December 29, 2023 | News

PharmaBlock Sciences Unveils State-of-the-Art High Potency API Facility in Zhejiang Site.

The new HPAPI GMP facility enables PharmaBlock to offer process R&D and kilo-scale production of HPAPIs and ADC toxins. It spans an area of 1...

 December 28, 2023 | News

FDA Grants Orphan Drug Designation to Boan Biotech's Two Novel Claudin 18.2 Drugs.

Orphan drugs, also known as drugs for rare diseases, are drugs for preventing, treating or diagnosing rare diseases. Being designated as orphan drugs will ...

 December 28, 2023 | News

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria. Drug resistance of anti...

 December 27, 2023 | News

GenSci Launches Global Innovation Hub in Shanghai

Changchun GeneScience Pharmaceutical ("GenSci"), a subsidiary of Changchun High-Tech Industries (Group), held a groundbreaking ceremony for its new global ...

 December 26, 2023 | News

Oncoshot Collaborates with Zhejiang Ablaze for Data-Driven Drug Development in China

This collaboration brings together complementary strengths - Oncoshot's capabilities in data analysis and insights generation with Ablaze's recent expansio...

 December 26, 2023 | News

TransThera Completes First Patient Dosing in US for Global Phase 3 Trial of Tinengotinib in FGFRi Relapsed/Refractory Cholangiocarcinoma

This study is a Phase 3, randomized, controlled, global multicenter study to evaluate the efficacy and safety of oral tinengotinib versus physician's choic...

 December 22, 2023 | News

Everest Medicines' Partner Calliditas Announces Nefecon® as Sole FDA-Approved Treatment for Slowing IgA Nephropathy Kidney Decline

The FDA approval is for adults with primary IgAN who are at risk for disease progression, irrespective of proteinuria levels. Nefecon® is now a...

 December 21, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in